Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 6, 2016, Pages 2432-2439

  Roussel, Ronan ^b   Boustany, Ray El ^a,c   Bouby, Nadine ^a,c   Potier, Louis ^a,b   Fumeron, Frédéric ^a   Mohammedi, Kamel ^a,b   Balkau, Beverley ^d   Tichet, Jean ^e   Bankir, Lise ^a,c   Marre, Michel ^a,b   Velho, Gilberto ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e IRSA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; ARGIPRESSIN; GLUCOSE BLOOD LEVEL; GLYCOPEPTIDE; INSULIN;

ADULT; ALLELE; ARTICLE; AVP GENE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRENCHMAN; GENE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; DIABETES MELLITUS, TYPE 2; FRANCE; GENETIC ASSOCIATION STUDY; GENETICS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ALLELES; ARGININE VASOPRESSIN; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FRANCE; GENETIC ASSOCIATION STUDIES; GLYCOPEPTIDES; HUMANS; HYPERGLYCEMIA; INCIDENCE; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 84973563241     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1113     Document Type: Article

References (40)

1. Laycock JF. Vasopressin and its interactions with other hormones and control systems. In: Laycock JF, ed. Perspectives on Vasopressin. London, UK: Imperial College Press; 2010:202-229.
2. Mavani GP, DeVita MV, Michelis MF. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin. Front Med. 2015;2:19.
3. Hems DA, Rodrigues LM, Whitton PD. Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions. Biochem J. 1978;172:311-317.
4. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J. 1978;176:893-898.
5. Koshimizu TA, Nakamura K, Egashira N, HiroyamaM, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: From molecules to physiological systems. Physiol Rev. 2012;92:1813-1864.
6. Taveau C, Chollet C, Waeckel L, et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015;58:1081-1090.
7. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism. 2002;51:1184-1190.
8. Aoyagi T, Birumachi J, Hiroyama M, et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148:2075-2084.
9. Fujiwara Y, Hiroyama M, Sanbe A, et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol. 2007;584: 235-244.
10. Nakamura K, Aoyagi T, Hiroyama M, et al. Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol. 2009;613:182-188.
11. Hems DA, Whitton PD, Ma GY. Metabolic actions of vasopressin, glucagon and adrenalin in the intact rat. Biochim Biophys Acta. 1975;411:155-164.
12. Spruce BA, McCulloch AJ, Burd J, et al. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol. 1985;22: 463-468.
13. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes. 1979;28:503-508.
14. Brooks DP, Nutting DF, Crofton JT, Share L. Vasopressin in rats with genetic and streptozocin-induced diabetes. Diabetes. 1989;38: 54-57.
15. Yi SS, Hwang IK, Kim YN, et al. Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem Res. 2008;33:833-841.
16. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
17. Morgenthaler NG. Copeptin: A biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16(suppl 1):S37-S44.
18. Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99: 4656-4663.
19. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046-1052.
20. Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973-3978.
21. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxyterminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94: 2558-2564.
22. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
23. Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E1065-E1072.
24. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012;55:1963-1970.
25. Then C, Kowall B, Lechner A, et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the populationbased KORA F4 study. Acta Diabetol. 2015;52:103-112.
26. Roussel R, Fezeu L, Bouby N, et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011;34:2551-2554.
27. The D.E.S.I.R. Study Group. An epidemiologic survey from a network of French Health Examination Centres. D.E.S.I.R. (Epidemiologic Data on the Insulin Resistance Syndrome). Rev Epidem et Sante Publ. 1996;44:373-375.
28. Balkau B, Lange C, Fezeu L, et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2008;31:2056-2061.
29. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva, Switzerland: WHO Press; 2006.
30. Cheurfa N, Brenner GM, Reis AF, et al. Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: The Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study. Diabetologia. 2011;54:554-562.
31. Roussel R, Matallah N, Bouby N, et al. Plasma copeptin and decline in renal function in a cohort from the community: The prospective D.E.S.I.R. Study. Am J Nephrol. 2015;42:107-114.
32. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765-769.
33. Thomas DC, Conti DV. Commentary: The concept of 'Mendelian randomization'. Int J Epidemiol. 2004;33:21-25.
34. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257-263.
35. Enhorning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond). 2013;37:598-603.
36. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2010; 77:29-36.
37. Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639-3645.
38. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab. 2015;100:3332-3339.
39. Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982;299:355-357.
40. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care. 2003;7:427-434. doi:10.1210/jc.2016-1113press.endocrine.org/journal/jcem2439The.